| Identification | Back Directory | [Name]
Onartuzumab | [CAS]
1133766-06-9 | [Synonyms]
Onartuzumab
Onartuzumab (anti-MET)
Research Grade Onartuzumab (DHC34202) |
| Hazard Information | Back Directory | [Description]
Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor. | [Clinical Use]
Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) . |
|
| Company Name: |
AntibodySystem
|
| Tel: |
17762345272 18162686757 |
| Website: |
www.antibodysystem.com |
|